Exonate
2013
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Early Stage VC
LATEST DEAL TYPE
12
INVESTORS
Description
Developer of small molecule drugs designed to modulate alternative mRNA splicing to address diseases of high unmet medical need. The company's lead program molecules, for wet Age-Related Macular Degeneration (wet AMD), act via a novel mechanism of action to inhibit pathological blood vessel and reduces formation of pathological VEGF (Vascular Endothelial Growth Factor) without inhibiting beneficial, non-pathological VEGF, enabling doctors to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- Unit 23, Cambridge Innovation Centre
- Cambridge Science Park, Milton Road
- Cambridge CB4 0EY
- England, United Kingdom
+44 01223 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Exonate’s full profile, request a free trial.
Exonate Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 12-Sep-2018 | 00.000 | Completed | Generating Revenue | ||
| 4. Grant | 06-Feb-2017 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 3. Early Stage VC | 01-Dec-2016 | 00.00 | 00.000 | 00.000 | Completed | Startup |
| 2. Early Stage VC | 05-Oct-2015 | $1.21M | $1.87M | 00.000 | Completed | Startup |
| 1. Seed Round | 01-Mar-2014 | $651K | $651K | 00.000 | Completed | Startup |
Exonate Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 00,000 | 00.000000 | 000 | 000 | 00 | 000 | 00.000 | |
| Ordinary | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Ordinary | 7,860 | $0.012459 | $62.29 | $62.29 | 1x | $62.29 | 14.1% |
Exonate Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | 0 | 0000 | 000000 0 | |
| 000000 00000000 | Formerly VC-backed | Palo Alto, CA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 00000000 | 00.000 |
| 000000 00000000000 | Venture Capital-Backed | Cincinnati, OH | 00 | 00000 | 000000 - 000 | 00000 |
| 0000000 000000 | Venture Capital-Backed | Redwood City, CA | 00000 | 00000000000 | 00000 |
Exonate Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Wellcome Trust | Limited Partner | 000 0000 | 000000 0 | |||
| Martlet | Angel Group | Minority | 000 0000 | 000000 0 | ||
| O2h Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Parkwalk Advisors | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Uniseed | Venture Capital | Minority | 000 0000 | 000000 0 |
Exonate Executive Team (5)
Exonate Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Andrew Naylor Ph.D | Self | Board Member | 000 0000 | |
| Catherine Beech MD | Exonate | Chief Executive Officer & Board Member | 000 0000 | |
| Christopher Torrance Ph.D | Self | Board Member | 000 0000 | |
| David Bates Ph.D | Exonate | Co-Founder, Board Member & Chief Scientific Officer | 000 0000 | |
| John Kurek Ph.D | Uniseed | Board Member | 000 0000 |